Dr. Al-Kali on FDA Approval of Enasidenib in AML

Partner | Cancer Centers | <b>Mayo Clinic Cancer Center</b>

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of enasidenib as a treatment for patients with relapsed or refractory IDH2-mutated acute myeloid leukemia (AML).

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of enasidenib as a treatment for patients with relapsed or refractory IDH2-mutated acute myeloid leukemia (AML).